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Increasing evidence suggests that hyperphosphorylation and aggregation of
microtubule-associated protein tau (MAPT or tau) correlates with the development
of cognitive impairment in Alzheimer’s disease (AD) and related tauopathies. While
numerous attempts have been made to model AD-relevant tau pathology in various
animal models, there has been very limited success for these models to fully recapitulate
the progression of disease as seen in human tauopathies. Here, we performed whole
genome gene expression in a genomic mouse model of tauopathy that expressed
human MAPT gene under the control of endogenous human MAPT promoter and also
were complete knockout for endogenous mouse tau [referred to as ‘hTauMaptKO(Duke)
′
mice]. First, whole genome expression analysis revealed 64 genes, which were
differentially expressed (32 up-regulated and 32 down-regulated) in the hippocampus of
6-month-old hTauMaptKO(Duke) mice compared to age-matched non-transgenic controls.
Genes relevant to neuronal function or neurological disease include up-regulated genes:
PKC-alpha (Prkca), MECP2 (Mecp2), STRN4 (Strn4), SLC40a1 (Slc40a1), POLD2
(Pold2), PCSK2 (Pcsk2), and down-regulated genes: KRT12 (Krt12), LASS1 (Cers1),
PLAT (Plat), and NRXN1 (Nrxn1). Second, network analysis suggested anatomical
structure development, cellular metabolic process, cell death, signal transduction, and
stress response were significantly altered biological processes in the hTauMaptKO(Duke)
mice as compared to age-matched non-transgenic controls. Further characterization of
a sub-group of significantly altered genes revealed elevated phosphorylation of MECP2
(methyl-CpG-binding protein-2), which binds to methylated CpGs and associates
with chromatin, in hTauMaptKO(Duke) mice compared to age-matched controls. Third,
phoshpho-MECP2 was elevated in autopsy brain samples from human AD compared
to healthy controls. Finally, siRNA-mediated knockdown of MECP2 in human tau
expressing N2a cells resulted in a significant decrease in total and phosphorylated
tau. Together, these results suggest that MECP2 is a potential novel regulator of tau
pathology relevant to AD and tauopathies.
Keywords: Alzheimer’s disease, tauopathies, tau protein, tau transgenic mice, methyl-CpG-binding protein-2,
MECP2, microarray
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INTRODUCTION
Tauopathies are a class of neurodegenerative diseases
characterized by the accumulation of hyperphosphorylated,
oligomeric and aggregated tau protein as NFTs (Lee et al., 2001).
A classic example of tauopathy is AD, which is the most common
neurological disease in the elderly leading to dementia. In
addition to AD, PSP, CBD, PiD, and FTDP-17 are other examples
of pure neurodegenerative tauopathies (Lee et al., 2001), where
dysfunctional tau is the primary driver of the disease. In a
majority of these neurodegenerative tauopathies, the non-
mutant form of tau has been shown to be the primary causative
factor. However, in FTDP-17, single point mutations in either
the splice-site or coding region of the MAPT gene has shown to
impair the structure and function of tau, inducing behavioral,
cognitive, and psychological impairments (Hasegawa, 2006).
A growing number of studies implicate reasonably significant
positive correlations between the build-up of NFTs and cognitive
impairment in various tau-targeted imaging studies in humans
(Nelson et al., 2012; Murray et al., 2015; Brier et al., 2016;
Ossenkoppele et al., 2016; Scholl et al., 2016). Although it is still
unclear how exactly hyperphosphorylated and/or aggregated tau
contributes to neurodegenerative processes, numerous studies
have suggested that tau-mediated pathological events occur
either via loss-of-function or gain-of-toxic function with regards
to microtubule interactions. Altering signaling pathways, like
Src/Fyn (Lee et al., 2004; Bhaskar et al., 2005; Vossel et al.,
2010; Morris et al., 2011), somato-dendritic localization affecting
synaptic function (Ittner et al., 2010; Ittner and Gotz, 2011),
impairing neurogenesis (Komuro et al., 2015), neuron-to-neuron
propagation and seeding of NFTs (Liu et al., 2012), as well as
Abbreviations: ABC, avidin:biotinylated enzyme complex; AD, Alzheimer’s
disease; ANOVA, analysis of variance; CBD, corticobasal degeneration;
CpG, 5′-C—phosphate—G-3′ (cytosine and guanine separated by only one
phosphate); DAB, 3,3’-diaminobenzidine tetrahydrochloride; EGFP, enhanced
green fluorescent protein; ETS, ETS proto-oncogene 1, transcription factor;
FDR, false discovery rate; FN3K (Fn3k), fructosamine 3 kinase; FOXK2 (Foxk2),
forkhead box K2; FTDP-17, fronto-temporal dementia and parkinsonism linked
to chromosome 17; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GH
(Gh or Gh1), growth hormone or growth hormone 1; GO, gene ontology;
IF, immunofluorescence; IHC, immunohistochemistry; IPATM, Ingenuity
Pathway Analysis; KRT12 (Krt12), type I intermediate filament chain keratin
12; LASS1 (Cers1), ceramide synthase 1; MAPT (Mapt), microtubule-associated
protein tau; MECP2 (Mecp2), methyl-CpG-binding protein 2; MED7 (Med7),
mediator complex subunit 7; NFT, neurofibrillary tangles; NFκB, nuclear factor
kappa-light-chain-enhancer of activated B cells; NRXN1 (Nrxn1), neurexin
1; p-PKCα, phosphorylated PKCα; PBST, phosphate buffer saline with 0.1%
tween; PCSK2 (Pcsk2), proprotein convertase subtilisin/kexin type 2; PiD, Pick’s
disease; PKC (Prkca), protein kinase C alpha; pMECP2, phosphorylated MECP2;
POLD2 (Pold2), polymerase (DNA) delta 2, accessory subunit; PSP, progressive
supranuclear palsy; PXR, pregnane X receptor; QC, quality control; qRT-PCR,
quantitative reverse transcription polymerase chain reaction; R-LIMMA, linear
models for microarray and RNA-sequence; RAPGEFL1 (Rapgefl1), rap guanine
nucleotide exchange factor like 1; RAR/RXR, retinoic acid receptors/retinoid
receptor; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis;
SFK, Src family kinase; SLC40a1 (Slc40a1), solute carrier family 40 member
1; STRN4 (Strn4), striatin 4; T-MECP2, total MECP2; T-PER, tissue protein
extraction reagent; T-PKCα, total PKCα; TSC22D3 (Tsc22d3), TSC22 domain
family member 3; VAT1L (Vat1l), vesicle amine transport 1-like; WDR18 (Wdr18),
WD repeat domain 18; WG6, whole genome 6; WT, wild type; YBX3 (Ybx3),
Y-box binding protein 3.
contributing to neuroinflammatory responses (Zilka et al., 2012)
are just a few of the suggested tau-mediated pathological events.
Over the past several years, tau pathology has been replicated
in several animal models of tauopathy that carry familial
mutations (Gotz et al., 2007). However, the tau pathology
observed is often in ectopic locations (Lewis et al., 2000)
and/or without overt neuronal cell death in these models
(Gotz et al., 2007). Davies and colleagues developed a genomic
mouse model of human tau pathology (HTau) expressing the
entire human non-mutant MAPT gene (Duff et al., 2000) in
a partial mouse Mapt deficient background (Andorfer et al.,
2003). Several previous studies have established that HTau
mice exhibit age-related hyperphosphorylation and aggregation
of MAPT (Andorfer et al., 2003), accumulation of NFTs and
displayed significant neuronal cell death (Andorfer et al., 2005).
While HTau mice displayed age-related tau pathology and
neurodegeneration, it was not clear if there was any influence by
the endogenous mouse tau, as the Mapt knockout mice utilized
to generate these HTau mice still retained 31 amino acids in
the N-terminal end of tau (Tucker et al., 2001). This is an
important factor to consider as we have previously demonstrated
that the N-terminal region of tau, which includes Tyr18, is a
substrate for the Src family non-receptor tyrosine kinase (SFKs,
for example: Fyn) (Lee et al., 2004) and can regulate SFK
signaling (Sharma et al., 2007) probably via interaction between
pTyr18 of tau with SH2 domain of SFKs. In a separate study,
Dawson et al. (2001) generated a separate Mapt−/− mice line
and crossed them to transgenic mice expressing human MAPT
to generate hTTg+/−/Mapt−/− mice. Primary neurons derived
from hTTg+/−/Mapt−/− mice displayed restoration of total
axonal length and total length of minor processes (compared
to Mapt−/− mice) in vitro. However, these studies were done
primarily in cell culture and further characterizations of these
mice are yet unavailable.
In the current study, we crossed HTau/Mapt+/+ mice [line
8C (Duff et al., 2000)] with the complete mouse Mapt knockout
mice (Dawson et al., 2001) to generate hTauMaptKO(Duke) and
identify novel gene(s) differentially regulated exclusively by the
expression of human MAPT via whole genome gene expression
analysis using Illumina R© WG6 microarray analysis. We further
assessed the protein levels of differentially expressed gene(s)
and their activation (phosphorylation) states in hTauMaptKO(Duke)
mice and also in human AD brains. Finally, we performed siRNA-
mediated knockdown studies to determine the relationship
between a newly identified gene, MECP2, in regulating tau levels
in in vitro model of tauopathy.
MATERIALS AND METHODS
Mice
The HTau (Andorfer et al., 2003) mice (expressing human
MAPT with partial deficiency for endogenous mouse Mapt, was
generated via targeted insertion of EGFP into the Mapt locus
hence referred to as Maptegfp/egfp) were bred and maintained
in our colony. Mice with a complete knockout of endogenous
mouse Mapt (Dawson et al., 2001) (Mapt−/−) were obtained
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from Jackson Laboratory (B6.129X1-Mapttm1Hnd/J – Stock #
007251). Both HTau and Mapt−/− mice were maintained in
the C57BL/6 background. We outbred HTau to the C57BL/6J
(non-transgenic) mice to obtain the 8c line (HTau mice with
Mapt+/+ background). The HTau/Mapt+/+ were then crossed
to Mapt−/− mice (Dawson et al., 2001) over at least 10
generations to develop hTau-Mapt−/− mice, which will be
referred to as hTauMaptKO(Duke) mice [‘MaptKO(Duke)’ refers
to ‘Mapt knockout mice generated at the Duke University by
Dawson’s group [published in Dawson et al. (2001) study]. All
comparisons were made to either 6- or 12-month-old non-
transgenic mice (referred to as WT). The WT mice were
littermates generated during hTauMaptKO(Duke) and Mapt−/−
breeding, but were without human MAPT transgene and were
Mapt+/+. We utilized mixed gender for all groups of mice in
the present study (Table 1). All experimental protocols involving
animals were performed in accordance with the US National
Institute of Health guidelines on animal care and were approved
by the Institutional Animal Care and Use Committee of the
University of New Mexico and Cleveland Clinic Foundation.
Antibodies and Reagents
Microtubule-associated protein tau antibodies: AT8
(pS202/pT205; mouse monoclonal antibody; ThermoFisher
Scientific; #MN1020), AT180 (pT231; mouse monoclonal
antibody; ThermoFisher Scientific; #MN1040), Tau-5 (or
Tau5; mouse monoclonal antibody; ThermoFisher Scientific;
#AHB0042), PHF-1 (pS396/pS404; mouse monoclonal antibody
provided by Peter Davies, Albert Einstein College of Medicine),
Tau12 (human tau specific antibody; mouse monoclonal
antibody; Abcam; #ab74137). Other antibodies: GAPDH (rabbit
polyclonal antibody; EMD Millipore; #ABS16), T-MECP2 (D4F3;
rabbit monoclonal antibody; Cell Signaling #3456); phospho-
MECP2 (pSer80; rabbit polyclonal antibody; PhosphoSolutions
#p1205-80).
Tissue Preparation for Biochemical
Analysis
The mice were anesthetized and transcardially perfused with
0.125 M phosphate buffer (PB). Following perfusion, the
brains were removed, the left hemisphere was immersion
fixed in 4% paraformaldehyde in PB (4% PFA/PB), the
right hemisphere was micro-dissected into the cortex and
hippocampus, wet weights were recorded, and the tissues were
snap frozen in liquid nitrogen for subsequent biochemical
analysis. The rest of the right hemispheres were weighed
and snap frozen in liquid nitrogen for subsequent mRNA
extraction. Hippocampi from 6- and 12-month-old WT and
hTauMaptKO(Duke) mice were used for biochemical (quantitative
real-time PCR/qRT-PCR or Western blot) analysis. Sagittal brain
sections were used for the immunohistochemical analysis (see
below).
RNA Extraction, Whole Genome
Microarray, and Gene Expression
Analysis
RNA from the hippocampus of 6-month-old non-transgenic
(or WT) and hTauMaptKO(Duke) mice (Table 1) was extracted
using the TRIzol R© reagent as described by the manufacturer
(Thermo Fisher Scientific), quantitated and 3 µg (30 µl at
100 ng/µl) of purified RNA converted to cRNA (High Capacity
cDNA synthesis kit, Thermo Fisher Scientific) and hybridized on
Illumina R© Mouse WG6 microarray chip (Pool_ID: 11278593_A;
Sentrix_ID: 6189772009; see the layout in Table 2). The
Illumina Mouse WG6 chip was a single chip that contains six
whole genome microarrays. Each of these six microarrays on
the WG6 chip contained 30,854 oligonucleotides (Figure 1A;
corresponding to over 23,000 well-characterized genes and over
10,000 predicted genes). Microarray chips were scanned using
Illumina’s state-of-the-art iScan R©. The raw data from iScan R©
were pre-processed in GenomeStudio and exported for further
data processing and analysis in R-LIMMA package (Law et al.,
2016).
For the gene expression analysis: Total RNA (50 ng/µL)
was converted to cDNA using the High Capacity cDNA
Reverse Transcription kit and amplified using specific TaqMan
probes (gene expression marker: Mecp2 Mm01193535_m1; MAPT
Hs00902194_m1) GAPDH was used as a house-keeping gene for
normalization. The qPCR assays were run on the StepOnePlus R©
Real-Time PCR System (all reagents were purchased from
Thermo Fisher Scientific).
SDS-PAGE and Western Immunoblotting
Proteins were homogenized in 10% weight/volume Tissue
Protein Extraction Reagent (T-PER R©, Thermo Fisher Scientific)
and soluble hippocampal lysates were resolved via SDS-PAGE
and immunoblotted as previously described (Bhaskar et al.,
2010b). The dilutions of primary antibodies utilized were as
follows: GAPDH at 1:20,000; Tau5 at 1:10,000; phospho- and
total-MECP2 at 1:1000.
TABLE 1 | Sample description.
Sample # Sample name Sample description Sex Sample group Sentrix ID Sentrix position
1 WT1 6-month-old WT M NM052412A 6189772009 A
2 WT2 6-month-old WT F NM052412B 6189772009 B
3 WT3 6-month-old WT F NM052412C 6189772009 C
4 hTau1 6-month-old hTauMaptKO(Duke) F NM052412D 6189772009 D
5 hTau2 6-month-old hTauMaptKO(Duke) F NM052412E 6189772009 E
6 hTau3 6-month-old hTauMaptKO(Duke) M NM052412F 6189772009 F
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TABLE 2 | Conditions and samples distribution.
Conditions Chip1
WT 1 2 3
hTauMaptKO(Duke) 4 5 6
The samples were not evenly distributed across chips.
Immunohistochemical Analysis
Free-floating sections (30 µm thick) from 12-month-old WT
and hTauMaptKO(Duke) mice as well as formalin fixed autopsy
brain sections from cognitively normal (Braak stage 0) and AD
(Braak Stage V) were processed for immunohistochemical (IHC)
and immunofluorescence (IF) analysis as previously described
(Bhaskar et al., 2010b). Briefly, sections were first incubated
in 10 mM sodium citrate buffer (pH 6.0) for 10 min at 95◦C
for antigen retrieval, washed in PBS with 0.1% Tween (PBST),
quenched with 0.3% H2O2 in PBST for 15 min (only for
IHC). Sections were blocked for 1 h at room temperature
with the 5% normal sera (goat/donkey – from animal species
in which the secondary antibodies were raised). The sections
were incubated with phospho-MECP2 (1:250). After washing in
PBST, the sections were incubated with biotinylated-secondary
antibody (1:250; Jackson ImmunoResearch Laboratories Inc.,
for IHC) or Alexa 555 conjugated goat anti-rabbit secondary
antibody (1:250 in blocking solution; for IF). Sections were
then incubated with ABC (Vector Laboratories) reagent for
1 h at room temperature (for IHC). The immunoreactive
signals were revealed by developing sections in SigmaFast R©
3,3’-diaminobenzidine (DAB) tablets (Sigma–Aldrich) (for IHC)
or the sections were mounted on slides using Hardset (Vector
Laboratories) with DAPI (for IF). Bright field images were
acquired using Leica DMR upright fluorescence, Leica TCS-SP8
confocal microscope and FLIM system or Olympus bright field
microscope.
Cell Lines and Transfections
Mouse neuroblastoma cells (Neuro2a or N2a cells; ATCC R©,
Manassas, VA, USA) were cultured in EMEM with L-glutamine
media with 10% FBS for up to 10 passages before being
expanded and plated at a density of 500,000 cells per well for
all the experiments. N2a cells were transiently transfected with
human tau plasmid (0.4 µg DNA per transfection), pRC/CMV
n123c (0N3R tau) using Effectine R© reagent per manufacturer’s
instructions (Qiagen, Cat# 301425). Mock (empty plasmid) or tau
transfected N2a cells were nucleofected with siRNA to MECP2.
After 24 h, the cells were lysed to detect MECP2, PHF1, Tau5,
Tau12, β-actin, and GAPDH via SDS-PAGE and Western blot
analysis (see above). Ratios of MECP2/GAPDH were plotted
to assess MECP2 knockdown and ratios of PHF1/Tau5 and
Tau5/GAPDH were plotted and quantified.
Statistical Analysis
Unless otherwise indicated, comparisons between the two groups
were done via unpaired t-test; comparisons between multiple
treatment groups were done via one-way or two-way ANOVA
with indicated multiple comparisons post hoc tests. All statistical
analyses were performed using GraphPad Prism R©.
RESULTS
The goal of the current study was to perform a whole genome
gene expression analysis in the humanized mouse model of
tau pathology that expressed only human tau in the complete
mouse tau knockout background. The expectations were two
fold; (1) to identify novel gene(s) that were significantly altered
in response to only human tau expression; and (2) to correlate
those significantly altered gene(s) with tau hyperphosphorylation
in hTauMaptKO(Duke) mice and in human tauopathy.
To obtain a genomic-based human mouse model of
tauopathy, we first outbred Htau mice [developed by Dr. Peter
Davies (Andorfer et al., 2003) to C57Bl/6J non-transgenic mice
and obtained human tau expressing mouse line called ‘8c’ (Duff
et al., 2000)]. The 8c line expresses all six isoforms of human
MAPT transgene driven by the endogenous human MAPT
promoter. The line 8c was then bred to the complete mouse
Mapt−/− mice, which were previously reported by Dawson et al.
(2001). The strategy for Mapt gene disruption utilized insertion
of a NEO cassette in place of exon 1 of the Mapt gene which
resulted in the complete replacement of exon 1 by NEO cassette
and lead to the total loss of endogenous mouse tau (Dawson
et al., 2001). We called these hTau (8c line) mice with complete
deficiency of endogenous mouse Mapt as hTauMaptKO(Duke) mice
[‘MaptKO(Duke)’ refers to Mapt−/− mice generated by Dawson
et al. (2001), from Duke University (published in Dawson et al.
(2001) study)]. These hTauMaptKO(Duke) mice are humanized
genomic mice, which express all six isoforms of human tau driven
by human MAPT promoter and are homozygous-deficient for
endogenous mouse Mapt.
A Small Number of Genes Are
Differentially Expressed in the
Hippocampus of 6-Month-Old
hTauMaptKO(Duke) Mice Compared to
Age-Matched Non-transgenic Mice
To identify differentially expressed mRNA levels in the
hippocampus of 6-month-old WT and hTauMaptKO(Duke) mice
(n = 3 per genotype; Table 1), we used an Illumina R© MouseWG-
6 V2 array chip to probe changes in 30,854 different mRNAs
(Figure 1A). A 6-month time point was selected based on, the
results from present study and several previous studies where
Htau mice have been shown to display significant increase in
tau phosphorylation in the hippocampus (Andorfer et al., 2003,
2005; Maphis et al., 2015). Overexpression of human MAPT in
hTauMaptKO(Duke) mice did not alter the overall number of mRNA
messages detected in the hippocampus between WT mice and
hTauMaptKO(Duke) mice that were relative to all the probes present
on the array (data not shown).
This primary whole genome microarray screen, which was
based on a small group size, resulted in generation of three
data sets: (1) the raw expression dataset exported directly from
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FIGURE 1 | Sample processing and cluster analysis approach. (A) Hippocampi from both hemispheres of 6-month-old non-transgenic (WT) and
hTauMaptKO(Duke) mice (n = 3 per genotype) were isolated, total RNA purified and profiled for 30,854 transcripts via MouseWG-6 v2.0 Expression BeadChip Kit
(Illumina R©), and the data was processed for downstream analysis. (B) Hierarchical clustering (unsupervised) with correlation distance (QC filtered detection
rate = 0.05) show WT-2 and WT-3 clustered together while WT-1 stayed separate. All three hTauMaptKO(Duke)-1-3 clustered together or close to each other.
(C) Volcano plot shows the relationship between –log10 (p-value) and log2 (fold change, FC) of all the genes being compared between WT and hTauMaptKO(Duke)
groups. Note the two criteria used in identifying the altered genes; (1) FDR adjusted p-value < 0.05; (2) Raw p-value < 0.001; up and down arrow depict up- or
down-regulated genes, respectively. (D) Expression intensities of all 30,854 normalized genes in the hippocampi of 6-month-old WT (n = 3) and 6-month-old
hTauMaptKO(Duke) (n = 3) mice, represented by red and blue, for high and low intensities, respectively. (E) Expression intensities of 64 genes that were significantly
altered in hTauMaptKO(Duke) mice compared to WT mice. Intensity scale is shown on the left of (E).
GenomeStudio, referred to as raw data; (2) the normalized
dataset, which was obtained based on the raw dataset after
force-positive background correction, log2 transformation and
quantile normalization; (3) the QC filtered dataset, which was
obtained based on the normalized dataset by selecting the
present probes using the detection threshold of p < 0.05.
The raw and normalized datasets had 30,854 genes and the
QC filtered dataset had 11,619 genes (Figure 1A). Next, QC
analysis was also performed on the normalized expression
data and the results are plotted as normalized box plot,
normalized control, normalized M (log ratios) and A (mean
average) scale plot, normalized pairs, and normalized sample
relation (Supplementary Figures S1–S4). Overall, the QC
analysis of the normalized data suggested that the generated
dataset was of good quality for the downstream analysis.
Next, hierarchical clustering (unsupervised) was performed
on the three data sets. Correlation distance was used in
all cases. Results suggested some association between sample
conditions and clustered grouping (Supplementary Figure S5).
For example, samples from WT-2 and WT-3 (non-transgenic
mice #2 and #3) segregated together. Similarly, samples
from hTauMaptKO(Duke)-2 and hTauMaptKO(Duke)-3 segregated
together. However, samples from WT-1 and hTauMaptKO(Duke)-
1 were separate from other samples in their respective groups
(Figure 1B and Supplementary Figure S5). Overall, there were
no outliers in the sample sets after the QC and clustering
analysis.
Next, comparisons were performed via linear modeling
to check differences between the two genotypes [WT and
hTauMaptKO(Duke)]. Empirical Bayes and other shrinkage methods
were used to borrow information across genes. FDR adjusted
p-values were calculated. Genes were defined as significantly
altered, if their FDR-adjusted p-value < 0.05. We also calculated
raw p-value and fold change. For the initial screening purposes,
the differentially altered genes were defined as those genes whose
adjusted p-value < 0.05 or raw p-value < 0.001 whichever was
smaller, and whose fold change was greater than the threshold
or less than 1/threshold in this analysis (Illumina R© recommends
1.35 for the threshold). A volcano plot analysis was performed
which showed the relationship between –log10 (p-value) and log2
(fold change) of all the genes between WT and hTauMaptKO(Duke)
groups. Genes scattered beyond the cut-off window in the
volcano plot indicated the statistical significance of gene
expression changes and provided a direct visual representation
of the genes that were differentially expressed. Based on the fact
that only four genes (Gh, Krt12, Mapt, and Rapgefl1; Table 3)
were altered between WT and hTauMaptKO(Duke) mice when we
used a strict FDR cut-off (of 2.0), we relaxed our criteria to
include genes that met both the raw p-value and fold change
(FDR cut-off of 1.5) (Figure 1C). Prior to relaxing our criteria the
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heat-map analysis of all 30,854 genes showed no obvious pattern
of significantly altered genes between WT and hTauMaptKO(Duke)
groups (Figure 1D). However, following relaxation of our criteria
(with a raw p-value of <0.001), 64 genes were either up-
or down-regulated in hTauMaptKO(Duke) mice compared to WT
group (Figure 1E and Table 3) and only these were utilized
for downstream functional pathway annotation and network
analysis via IPATM, MetacoreTM, and GO (Table 3). Some of
the differentially regulated genes, proteins they encode, their
function and their relevance to the brain function are shown in
Supplementary Table S1.
A Majority of the Altered Genes Are
Regulated by the Transcription Factor
SP1 and Are Associated with Anatomical
Structure, Development, Metabolic
Process, and Cell Death
To obtain an inventory of all the up- and down-regulated
genes between WT and hTauMaptKO(Duke) mice, we plotted all
64 significantly altered (raw p < 0.001) genes displaying a
cut-off of +1.5-fold change (Figure 2A). Interestingly, exactly
half of the 64 genes (i.e., 32) were down-regulated and the
remaining half was up-regulated (Figure 2A). The most down-
regulated gene was C330006P03RIK, which is an unclassified
gene of unknown function. The most up-regulated gene, yet
with only ∼0.5 log fold change, was Vat1L protein, which is
a protein-coding gene with functions related to oxidoreductase
activity and transferase activity (source: GeneCards and GO
annotations) (Figure 2A). Mecp2 and Wdr18 were among the
lowest (<0.25-fold) up- or down-regulated genes, respectively
(Figure 2A). While Mecp2 was the gene with the lowest level
of upregulation in hTauMaptKO(Duke) mice, it is highly relevant
to our analysis because of its involvement in the regulation of
DNA methylation. Furthermore, a mutation in the MECP2 gene
in humans is the primary cause of most cases of Rett Syndrome
(Joyner et al., 2009; Petazzi et al., 2014), a rare genetic postnatal
neurological disorder predominantly affecting females. Next, we
performed network analysis using MetacoreTM to identify which
transcription factor(s) would regulate the expression of the most
number of genes from our screening. As shown in Figure 2B,
SP1 transcription factor appeared to regulate 9 of the significantly
altered genes (Mapt, Strn4, Mecp2, Slc40a1, Fn3K, Pcsk2, Prkca,
Lass1, and Pold2) in our panel compared to other transcription
factors: NFκB, PXR, ETS, RAR-α/RXR-β, p53, p73 or AP-1,
which only appeared to regulate anywhere between 1 and 4 genes
(Figure 2B).
Next we performed process and phenotype annotations for
the genes that are significantly altered in the hTauMaptKO(Duke)
mice using MetacoreTM, IPATM, and GO. There were overlaps
in certain functional terms between these analyses. For example,
the enrichment analysis from these publicly available software
packages showed that the following process/functions were
pronounced in hTau mice: “Regulation of protein modification
and metabolic processes, acetylation, protein-protein
interaction, protein ubiquitination, regulation of apoptosis,
cell surface receptor linked signal transduction,” etc., while
“alternative splicing, metal binding, presence of WD40 motif
proteins, secretory pathway” were relatively suppressed in
hTauMaptKO(Duke) compared to WT. The protein modification,
ubiquitination, protein transport, cytoskeletal remodeling,
inflammation, etc., were some of the key process/function terms
that surfaced from the IPA/Metacore analysis. To identify the
most relevant set of genes that overlapped with more than
one functional GO terminology, and the set of genes that
would be most relevant to neurological diseases, we plotted
the top six biological process categories from the GO analysis
and mapped genes that were up- (red) or down-regulated
(blue) within each of these biological processes. The top six
GO biological process and the gene representations were; (a)
anatomical structure development (17/47 genes; 36.17%); (b)
cellular nitrogen compound metabolic process (15/47 genes,
31.91%); (c) biosynthetic process (13/47 genes, 27.66%); (d)
cell death (9/47 gene, 19.15%); (e) signal transduction (8/47
genes, 17.02%); and (f) response to stress (8/47 genes; 17.02%)
(Figure 2C). Differentially altered genes associated with these six
biological processes were split into two groups and plotted as two
Venn diagrams (Figure 2C). The intersection included Mecp2↑
and Prkca↑ (arrows indicate these are up-regulated) as key
genes common for both sets of Venn diagrams. The overlapping
region also included Foxk2↓, Med7↓, Ybx3↓, and Tsc22d3↓
(arrows indicate these are down-regulated). However, these were
absent in the second set of Venn diagram (Figure 2C). We also
plotted a third Venn diagram with ‘neurological system process’
(5/47 genes; 10.64%), ‘immune system process’ (5/47 genes;
10.64%), and ‘cell cycle’ (3/47 genes; 6.38%) as three additional
biological/disease-relevant processes. While Prkca was the only
gene present in the overlapping region, Mecp2 was clearly unique
to ‘neurological system process’ (Figure 2C). Taken together,
these results suggest that Prkca and Mecp2 are the most common
genes relevant to several biological processes, which may have
been altered in the hippocampus of hTauMaptKO(Duke) mice
compared to WT controls.
Mecp2 Is Significantly Altered in
hTauMaptKO(Duke) Mice and Human AD
Brain
Whereas Prkca is a generic protein kinase that affects multiple
cellular pathways, the Mecp2 is one of the altered genes present
in the interface of all three biological processes from the
TABLE 3 | Description of gene selection for pathway analysis.
Total genes studied 30,854
QC filtered genes 11,618
Significantly altered [all are
down-regulated in hTauMaptKO(Duke)
mice] genes in hTauMaptKO(Duke) vs. WT
mice (Based on raw p-value 10−6 and
FDR cut-off < 0.05)
4 (Gh, Krt12, Mapt, and
Rapgefl1)
Genes after relaxing the statistical
criteria (Raw p-value of <0.001)
64
Number of genes used for GO, IPATM,
MetacoreTM studies
62 (2 were obsolete)
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FIGURE 2 | Microarray analysis of the hippocampi of 6-month-old WT and hTauMaptKO(Duke) mice. (A) Total RNA from hippocampi of 6-month-old WT and
hTauMaptKO(Duke) mice was hybridized to MouseWG-6 v2.0 Expression BeadChip (Illumina R©). Expression of 64 genes that were significantly altered in
hTauMaptKO(Duke) mice compared to WT is shown. Values displayed as fold change in expression level: up-regulated (red) and down-regulated (blue) genes. Data
represents mean fold change from three mice per genotype. (B) Gene interaction network analysis (using Metacore analytical suite) for the 64 significantly altered
genes in hTauMaptKO(Duke) mice compared to WT mice. The genes with red (or blue) next to their graphic key is either up- (or down-) regulated. As expected,
endogenous mouse tau (MAPT) is one of the most down-regulated genes. Other genes relevant to neuronal function or neurological disease include Prkca, Mecp2,
Strn4, Slc40a1, Pold2, Pcsk2 (up-regulated) and Krt12, Lass1, Plat and Nrxn1 (down-regulated). Many of the altered genes are regulated by the transcription factor
SP1. (C) Venn diagrams showing GO’s biological processes when all 64 genes are categorized for top biological processes segregate into three distinct Venn
diagrams: Group 1: anatomical structure development – 17 altered genes out of total 47, i.e., 17/47; cellular nitrogen compound metabolic process – 15/47;
biosynthetic process 13/47. Group 2: cell death – 9/47; signal transduction 8/47; response to stress 8/47. Group 3: neurological system 5/47, cell cycle 2/47 and
immune system processes 4/47. Note the genes written in red (or blue) are significantly up- (or down-) regulated.
GO analysis and is directly implicated in neurological diseases
(Rett Syndrome). Therefore, we decided to determine the total
protein levels and phosphorylation status of MECP2 in the
hippocampus of non-transgenic and hTauMaptKO(Duke) mice. To
confirm our microarray data, we first assessed Mecp2 mRNA
levels via real-time quantitative PCR analysis and observed
an expected increase in the MECP2 mRNA levels in the
hemi-brains of 6-month-old hTauMaptKO(Duke) mice compared
to age-mated WT controls (Figure 3A). Next, we determined
the regional differences in the MECP2 mRNA levels with
hTauMaptKO(Duke) mice at 6 months of age. Interestingly, we
observed cortex displaying significantly highest levels of MECP2
mRNA compared to hippocampus and rest of the brain (ROB),
which are enriched in striatum, diencephalic structures, brain
stem but lacked cortex/hippocampus (Figure 3B). We also
assessed the mRNA levels of Vat1l, which was up-regulated
in the microarray analysis. There was an increased trend
for Vat1l, but the statistical significance was at p = 0.06
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FIGURE 3 | MECP2 expression and phosphorylation is up-regulated in 6-month-old hTauMaptKO(Duke) mice. (A) qRT-PCR analysis showing statistically
significant (∗p < 0.05; unpaired t-test; n = 4 WT, and n = 4 for hTauMaptKO(Duke) mice; mean + SEM) up-regulation of MECP2 in the hemi-brains of 6-month-old
hTauMaptKO(Duke) vs. WT mice. (B) Note the regional differences in the expression of MECP2 in the hippocampus (HIP), cortex (CX), and rest of the brain (ROB) that
are devoid of CX and HP. (C) Another gene (Vat1l) that was increased in our whole genome microarray analysis also showed modest up-regulation in its mRNA levels
in the brains of hTauMaptKO(Duke) mice compared to age-matched WT mice. (D,E) Western blot analysis showing a trend toward increased levels for
phospho(p)-Ser80 MECP2/total (t) MECP2 and tMECP2/GAPDH [p = 0.08; unpaired t-test; n = 3, all females for WT and n = 10, three females and six males for
hTauMaptKO(Duke)] in 6-month-old hTauMaptKO(Duke) versus WT mice; mean + SEM). (F) Double IF and confocal microscopy analysis revealing a modest increase in
pMECP2 in the CA3 region of HP in 6-month-old hTauMaptKO(Duke) mice compared to age-matched WT controls. Scale bar 25 µm.
(Figure 3C). Next, we prepared hippocampal lysates from
6-month-old WT and hTauMaptKO(Duke) mice. The levels of
both phosphorylated at Ser80 (p)MECP2/total (t)MECP2 and
tMECP2/GAPDH appeared elevated in the hippocampus of
6-month-old hTauMaptKO(Duke) mice compared to 6-month-old
WT controls (Figures 3D,E). However, only the total (t)MECP2
levels appeared increased more than three folds compared to
WT controls (Figures 3D,E), yet statistical analysis suggested
p = 0.08 despite having n = 10 mice in hTauMaptKO(Duke) group
(Figures 3D,E). This could be due to high variability in the
levels of both pMECP2 and tMECP2 at 6-months of age in
both WT and hTauMaptKO(Duke) groups. Finally, we performed
double IF analysis for pMECP2 and DAPI to determine if the
pMECP2 levels reveal elevated labeling within specific cellular
population in the hippocampus. Both 6-month-old WT and
hTauMaptKO(Duke) mice showed basal level of, mostly nuclear,
labeling for pMECP2, which appeared slightly increased as a
heterochromatic speckles within the nucleus of the CA3 region
of hTauMaptKO(Duke) mice compared to WT mice (Figure 3F).
Together these results suggests that because the MECP2 mRNA
levels are only marginally up-regulated in the whole genome gene
expression and mRNA analysis, the MECP2 protein levels did
not reach desired statistical significance in the hippocampus of
hTauMaptKO(Duke) mice.
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FIGURE 4 | MECP2 phosphorylation is up-regulated in 12-month-old hTauMaptKO(Duke) mice and in human AD brain. (A,B) Western blot analysis showing
pMECP2/GAPDH ratio significantly higher [∗p < 0.05; unpaired t-test; n = 3 for hTauMaptKO(Duke) versus WT mice; all three males for WT; two males and one female
for hTauMaptKO(Duke); mean + SEM] in the hippocampus of 12-month-old hTauMaptKO(Duke) mice compared to WT controls. No alteration in the tMECP2/GAPDH ratio
in the hippocampus of 12-month-old hTauMaptKO(Duke) mice compared to controls. (C) Significantly elevated pMECP2 immunoreactive specks within the nucleus of
CA3 hippocampal neurons of 12-month-old hTauMaptKO(Duke) mice compared to age-matched WT controls. (D) Double IF and confocal microscopy analysis shows
a modest increase in the pMECP2 in the CA3 neuronal layer of 12-month-old hTauMaptKO(Duke) mice compared to age-matched WT controls. (E–G) Confocal
projections (in E,G) and bright field images show elevated pMECP2 immunoreactivity and co-localization with nuclear stain DAPI (in E,G) or peri-vascular labeling
(in F) specifically in the Layer III of temporal cortex of human AD brain autopsy sections compared to the to non-AD healthy control subject. Orthogonal view in (G)
shows pMECP2 labeling to be nuclear or peri-nuclear in the human AD cortex. Scale bar 10 µm (in C,F); 25 µm (in D,G); 100 µm (in E).
To determine if the differences in MECP2 between WT and
hTauMaptKO(Duke) mice stands out to be statistically significant
with age, we performed Western blot analysis in 12-month-old
WT and hTauMaptKO(Duke) mice. There was no significant
alteration in the levels of T-MECP2 protein at 12-months of age
(Figures 4A,B). However, the level of pMECP2 was significantly
up-regulated in the hippocampus of hTauMaptKO(Duke) mice
compared to WT mice (Figures 4A,B). Elevated levels of
pMECP2 were also observed within the nuclei of CA3 pyramidal
neurons in hippocampus of hTauMaptKO(Duke) mice compared
to WT group, which again appeared more like speckle
staining mostly at heterochromatin regions of the nucleus
(Figure 4C). We confirmed this by performing double IF
followed by confocal microscopy analysis. Twelve-month-old
hTauMaptKO(Duke) mice displayed markedly elevated pMECP2
labeling that overlapped with nuclear staining DAPI in
the CA3 regions of hippocampus (Figure 4D). Finally, to
determine if the pMECP2 is relevant to human AD, we
probed autopsied brain sections from a human AD patient
and compared that from a non-demented control subject.
Confocal microscopy analysis revealed numerous cells positive
for pMECP2 in the layer III (temporal cortex) of human AD
brain compared to non-AD controls (Figure 4E). Interestingly,
we observed significantly more pMECP2 immunoreactive
structures, which appeared to be peri-vascular and picnotic
(Figure 4F arrows) and sometimes nuclear/peri-nuclear in
layer III of the temporal cortex (Figures 4F,G). Confocal
microscopy did show presence of somewhat cytosolic or
diffused nuclear staining for pMECP2 in non-AD controls
(Figure 4G), which was readily visible in the IHC via bright
field microscopy (Figure 4F). These results reveal higher
levels of pMECP2 in both the CA3 hippocampal neurons of
hTauMaptKO(Duke) mice and in the temporal lobe of human AD
patients.
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FIGURE 5 | MECP2 regulates tau pathology in vitro. N2a cells transiently transfected with human tau 0N3R isoform (‘+Tau’) or a control plasmid (‘−Tau’) were
nucleofected with siRNA [scramble siRNA (siScr) or MECP2 siRNA]. After 24 h of siRNA nucleofection, the cells were harvested and probed for AT180, PHF-1, Tau5,
Tau12, and T-MECP2. (A,B) Note that siMECP2 significantly reduced levels of MECP2 in both ‘−Tau’ and ‘+Tau’ N2a cells (∗p < 0.01; unpaired t-test; n = 3
replicates; mean + SEM). (C,D) siMECP2 treatment also significantly (∗p < 0.01; unpaired t-test; n = 3 replicates; mean + SEM) reduced the levels of both total tau
(Tau5/GAPDH) and human tau (Tau12/GAPDH) ratios in the ‘+Tau’ N2a cells compared to scramble siRNA treated conditions. (E–H) siMECP2 knockdown resulted
in statistically significant (∗p < 0.01; unpaired t-test; n = 3 replicates; mean + SEM) increase and decrease in AT180/Tau5 and PHF1/Tau5 ratios, respectively. Note
that the ratio for β-actin/GAPDH was not altered either in ‘−Tau’/‘+Tau’ conditions or with/without siMECP2 conditions.
Mecp2 Regulates the Levels of Total and
Phosphorylated Tau Protein
Since the MECP2 levels are elevated in hTauMaptKO(Duke) mice and
in human AD, we wanted to determine if MECP2 could directly
regulate the total and phosphorylated levels of tau protein.
Therefore, we transiently transfected N2a cells with either human
tau (non-mutant 0N3R isoform) or control plasmid. After 24 h,
the N2a cells were nucleofected with either MECP2 siRNA
(siMECP2) or scrambled siRNA (siScr). As expected, human
tau transfected N2a cells expressed human tau (positive for
Tau12 antibody) and displayed hyperphosphorylation on the
T231 (AT180) and Ser396/Ser404 (PHF1) sites (Figures 5E,F).
Further, siRNA against MECP2 showed >80% reduction in the
T-MECP2 levels compared to siScr control group (Figures 5A,B).
Interestingly, both hyperphosphorylated (on PHF1 site) and total
tau (Tau5/GAPDH and Tau12/GAPDH) levels were significantly
reduced following siRNA-mediated knockdown of MECP2 in
tau transfected N2a cells (Figures 5C,D). On the other hand,
most intriguingly, there was an increase in AT180/Tau5 ratio
with siRNA-mediated knockdown of MECP2 was observed
(Figures 4A, 5E). To determine if MECP2 knockdown specific
to reducing tau levels or could act as a suppressor of generic
transcription; we assessed the immunoreactivity for β-actin.
While there was small reduction in β-actin/GAPDH ratio
in with siMECP2 in both ‘+/− Tau’ conditions (Figures
5A,G,H), however, the effects were not statistically significant
as the one observed for Tau5/GAPDH and Tau12/GAPDH
(Figures 5A,C,D). Together, these results suggest that MECP2
may directly or indirectly regulate expression of tau and its
phosphorylation state, which may be relevant to AD and related
tauopathies.
DISCUSSION
We report here on the generation and use of a new line of
human tau transgenic mice (hTauMaptKO(Duke)) via crossing two
previously reported mouse lines [line 8c – (Duff et al., 2000)
and complete mouse tau knockout line (Dawson et al., 2001)].
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We performed a whole genome gene expression analysis in the
hippocampus of hTauMaptKO(Duke) mice and compared it with
age-matched control (WT) mice. Our results identified a small
number of genes differentially expressed in hTauMaptKO(Duke)
mice compared to non-transgenic control groups. Among them
Mecp2 was highly relevant to neurological conditions such
as Rett syndrome [reviewed in (Feldman et al., 2016)] and
Autism (Loat et al., 2008). While T-MECP2 levels were not
specifically altered in the hippocampus of aged hTauMaptKO(Duke)
mice, the active form (phosphorylated at Ser80) of MECP2
was significantly elevated in the hTauMaptKO(Duke) compared to
age-matched control mice. Finally, siRNA-mediated deficiency of
MECP2 resulted in altered phosphorylation of tau (on AT180 and
PHF1 sites) and significantly altered total tau levels in an N2a cell
culture model of tauopathy, indicating an regulatory relationship
between MECP2 and tau phosphorylation.
Our goal to generate hTauMaptKO(Duke) mice with a complete
deficiency of endogenous mouse tau was prompted by the
lack of genomic models available where the endogenous MAPT
promoter drives the expression of human MAPT in the Mapt
null genetic background. The choice of such mouse model
allows identification of differentially expressed genes due to the
exchange of human tau against mouse tau. This could be of
interest since tauopathies including AD are specific to humans
and therefore might be related to specific feature of human tau
compared to mouse tau. While the HTau mice developed by
Davies and colleagues did display all the pathological features
of tauopathies, endogenous Mapt deficiency was incomplete.
Since these HTau mice retained the first 31 amino acids at the
N-terminus of endogenous mouse Mapt and previous studies
from our group (Lee et al., 2004; Bhaskar et al., 2005, 2010a;
Sharma et al., 2007) and others (LaPointe et al., 2009; Pooler
and Hanger, 2010) have demonstrated important functions for
the N-terminal part of tau, we generated hTauMaptKO(Duke) mice
on a complete mouse Mapt null background for whole genome
gene expression analysis. Furthermore, because the human
MAPT is driven by endogenous human MAPT promoter, any
differentially regulated genes in hTauMaptKO(Duke) mice would
more closely relate to the human condition than those from
cDNA based mouse models of tauopathy – many of these
carry mutations in MAPT gene and may only be relevant to
FTDP-17. While numerous genome-wide association (GWAS)
studies have been performed in AD and have identified several
risk alleles, single nucleotide polymorphism (SNPs), and/or
haplotypes, there are very limited GWAS studies conducted in
human populations investigating pure tauopathy. Recently, the
first PSP GWAS identified three non-MAPT susceptibility loci at
STX6, EIF2AK3, and MOBP (Hoglinger et al., 2011). In another
recent GWAS study in CBD cases, additional association of the
SOS1 and lnc-KIF13B-1 along with overlapping associations of
MOBP to both PSP and CBD were discovered (Kouri et al.,
2015). Three additional candidate genes ABCA7, DYSF, and
PAXIP1 showed association in another recent multi-ancestral
GWAS study of AD, FTD, and PSP (Chen et al., 2015). The
most recent GWAS study in a population of PSP suggested
that brain levels of LRRC37A4 and ARL17B were associated
with rs8070723; MOBP with rs1768208 and both ARL17A and
ARL17B with rs242557 (Allen et al., 2016). Interestingly, authors
discovered strong association between risk alleles and CpG
methylation in several-associated genes/loci including MAPT,
MOBP, ARL17A, and ARL17B (Allen et al., 2016). When
we performed heat-map analysis for the normalized dataset
for some of the PSP/CBD associated genes (PAXIP1, SOS1,
DYSF, EIF2AK3, STX6, ABCA7, MOBP, and MAPT) in our
whole genome screen, we noticed a very clear segregation of
hTauMaptKO(Duke) and WT mice (Supplementary Figure S6).
Most importantly, MOBP segregated with MAPT and ABCA7,
while STX6 was closer to MAPT/MOBP (Supplementary Figure
S6). The common link between our study and previously
published human GWAS studies is the role of epigenetics
in regulating the expression of key genes/associated loci by
MECP2, which is a DNA methylation protein implicated in
Rett syndrome (Amir et al., 1999), autism (Loat et al., 2008),
mental retardation (Shahbazian and Zoghbi, 2001), and mild
learning disabilities (Shibayama et al., 2004). MECP2 has
been classically defined as a suppressor of transcription due
to its binding to methylated CpG dinucleotide, resulting in
tighter winding of the chromatin coil and reduced transcription
(Joyner et al., 2009). A MECP2 haplotype was shown to
be associated with reduced cortical surface area in humans
in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
study (Joyner et al., 2009). Defective MECP2 function has
also been implicated in neural tube defect (Petazzi et al.,
2014), abnormal spine dynamics (Jiang et al., 2013), impaired
neuronal excitability (Zhang et al., 2014), and oxidative brain
damage (De Felice et al., 2014). Although the overall number
of significantly altered genes were minimal in hTauMaptKO(Duke)
compared to WT mice, some of them have been implicated
in human PSP/CBD. Finally, a previous study attempted to
perform cell specific micro-array analysis in the HTau mice via
micro-aspiration of CA1 pyramidal neurons by laser capture
microdissection and custom micro-array analysis of 576 genes
(see Supplementary Figure S7). Approximately, 8% (42 genes)
of the genes were differentially regulated in the CA1 neurons
from Htau mice compared to controls and these genes were
associated with decreased synaptic function and neuron survival
(see Supplementary Figure S7). We selected these 42 differentially
regulated genes (identified in Alldred et al., 2012) from our
normalized whole genome gene expression data sets and
plotted for WT and hTauMaptKO(Duke) mice. As expected, mouse
Mapt was significantly higher in the WT mice compared to
hTauMaptKO(Duke) mice (Supplementary Figure S7). Interestingly,
some of the genes (for example Arc) that were down-regulated
in Alldred et al. (2012) study also appeared to be slightly
down-regulated in the hTauMaptKO(Duke) mice (Supplementary
Figure S7).
MetacoreTM-based network analysis identified SP1
transcription factor as one of the principle transcription
factors regulating nine (out of 64) differentially altered genes
in the hTauMaptKO(Duke) mice. Notably, SP1 transcription factor
responds to inflammatory signals and has been shown to be
up-regulated in human AD brain, as well as in the brains
of mouse models of AD (Citron et al., 2008). In a recent
study, pharmacological inhibition of SP1 in a mouse model of
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AD resulted in accelerated amyloid pathology and impaired
cognitive function (Citron et al., 2015). Finally, various neuronal
pro-survival factors (Bcl-2, Bcl-x, and surviving) have been
shown to be targets of SP1 (Ryu et al., 2003), suggesting the need
for in-depth analysis of the role of SP1 in tauopathies.
CONCLUSION
We report here on hTauMaptKO(Duke) mice as a novel humanized
mouse model of tauopathy with complete deficiency of
endogenous mouse Mapt. The hTauMaptKO(Duke) mice display tau
hyperphosphorylation on multiple serine and threonine residues
relevant to AD/tauopathies. Whole genome gene expression
analysis revealed a limited number of genes differentially
altered in hTauMaptKO(Duke) mice when the FDR cut-off was
stringent. Upon relaxation of the criteria and consideration
of raw significance of p < 0.001, 64 genes were found to be
differentially expressed in the hippocampus of hTauMaptKO(Duke)
mice compared to non-transgenic control mice. Importantly,
SP1 transcription factor and MECP2 were identified as two
key regulators implicated in hTauMaptKO(Duke) mice. Notably,
siRNA-mediated deficiency of MECP2 resulted in reduced total
and phosphorylated tau levels in human tau expressing N2a cell
culture model of tauopathy. Together, our results suggest that
MECP2 may be a key regulator of tauopathy and future studies
exploring the relationship between MECP2 and tau is important
in understanding the molecular mechanisms of tauopathy.
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